Clinical Development
ByJ&J’s $1 Billion Firefly Bio Buy: Has Big Pharma Finally Found a Way to Drug the ‘Undruggable’ KRAS?
Key Highlights A Novel Modality for a Notoriously Hard Target At the center of the acquisition is Firefly…
Can a Single Injection Change Everything? Novartis’s Itvisma Wins EU Approval for Broader SMA Population
Key Highlights Closing a Long-Standing Treatment Gap Itvisma’s approval extends gene replacement therapy to an SMA population that…
Can Novartis’s Up to $1.5 Billion Acquisition of Myricx Bio Unlock a New Generation of Cancer-Fighting Antibody-Drug Conjugates?
Key Highlights A Landmark Exit for Early-Stage Science Brandon Capital’s exit from Myricx Bio represents one of its…
Can Novo Nordisk’s Newly EU-Approved Wegovy Pill Make Weight Loss Treatment as Simple as Taking a Daily Tablet for Millions Across Europe?
Key Highlights A Landmark Shift From Injection to Tablet The European Commission’s authorization marks the first time a…
Is Eli Lilly’s Reported $2 Billion Pursuit of AtaiBeckley About to Redefine the Future of Psychedelic Medicine?
Key Highlights A Premium Bet on Psychedelic Innovation Eli Lilly is negotiating a takeover of AtaiBeckley at a…
Will Big Pharma’s Billion-Dollar AI Investments Reshape the US$2 Trillion Pharmaceutical Industry Faster Than the Next Blockbuster Drug?
Key Highlights The AI Investment Race Has Officially Begun Artificial intelligence has rapidly evolved from an experimental technology…
